FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
MyMD Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company committed to developing novel therapi
Read at businesswire.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
UBX | Unity Biotechnology | 4.17 | ||||
RXRX | Recursion Pharmaceuticals | 3.58 | ||||
GOVX | GeoVax Labs | 2.26 | ||||
DSGN | Design Therapeutics | 2.25 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
KZR | Kezar Life | 1.86 | ||||
NVCT | Nuvectis Pharma | 1.53 | ||||
XBIO | Xenetic Biosciences | 1.47 | ||||
REPL | Replimune | 1.30 | ||||
LYRA | Lyra Therapeutics | 1.18 | ||||
AVIR | Atea Pharmaceuticals | 0.31 | ||||
PASG | Passage Bio | 0.15 | ||||
SRZN | Surrozen | 0.08 | ||||
NBY | NovaBay Pharmaceuticals | 0 | ||||
LGND | Ligand Pharmaceuticals | 0.37 | ||||
KRON | Kronos Bio | 1.04 | ||||
LYEL | Lyell Immunopharma | 1.61 | ||||
ORIC | Oric Pharmaceuticals | 1.68 | ||||
GOSS | Gossamer Bio | 2.33 | ||||
KROS | Keros Therapeutics | 2.39 | ||||
REVB | Revelation Biosciences | 3.23 | ||||
LRMR | Larimar Therapeutics | 4.55 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |